Faruqi & Faruqi Investigates Securities Fraud Claims Against Picard Medical
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 28 2026
0mins
Should l Buy PMI?
Source: PRnewswire
- Securities Fraud Investigation: Faruqi & Faruqi LLP is investigating potential securities fraud claims against Picard Medical, urging investors who suffered losses between September 2 and October 31, 2025, to seek lead plaintiff status by the April 13, 2026 deadline, thereby providing legal support for affected investors.
- Stock Price Plunge: On October 24, 2025, Picard Medical's shares plummeted from $13.20 to $5.31, a staggering drop of $7.89 or approximately 59.8% in a single day, marking one of the most significant declines since the company's IPO, reflecting severe market concerns about its financial health.
- False Promotion Allegations: The lawsuit alleges that Picard Medical and its executives violated federal securities laws through false statements and failure to disclose risks associated with a fraudulent stock promotion scheme, which may expose investors to significant losses and intensify scrutiny over the company's governance practices.
- Legal Action Opportunity: Faruqi & Faruqi encourages all individuals with information regarding Picard Medical's conduct, including whistleblowers and former employees, to contact the firm to support the ongoing class action lawsuit, ensuring that all affected investors can seek the legal remedies they deserve.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PMI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PMI
About PMI
Picard Medical, Inc. is a holding company that owns a 100% interest in SynCardia Systems, LLC (SynCardia). SynCardia is a medical technology company that manufactures and sells the only United States Food and Drug Administration (FDA) and Health Canada-approved implantable total artificial heart (SynCardia TAH). The SynCardia TAH is a biventricular replacement device that consists of the SynCardia TAH implant, an external pneumatic driver that delivers precisely calibrated pulses of air to drive the implant, and drivelines that connect the driver to the implant. The SynCardia TAH implant is a system that consists of two independent artificial ventricles which are powered by an external pneumatic driver. Each artificial ventricle is made of a semi-rigid polyurethane housing and a rigid polyurethane base, with a four-layer flexible polyurethane diaphragm separating the blood chamber from the air chamber.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Picard Medical Securities Class Action Notice Issued
- Class Action Initiation: Rosen Law Firm has issued a reminder for investors who purchased Picard Medical (NYSE: PMI) securities between September 2 and October 31, 2025, to apply as lead plaintiffs by April 13, 2026, to protect their rights in the class action lawsuit.
- Transparent Fee Structure: Investors joining the class action will incur no upfront costs, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages more affected investors to participate.
- False Statements Exposed: The lawsuit alleges that Picard Medical failed to disclose significant adverse facts related to its business and securities trading during the class period, including fraudulent stock promotion schemes and insider trading, misleading investors about the company's true financial health.
- Law Firm's Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource capabilities in handling such cases.
See More
Multiple Companies Face Class Action Lawsuits
- Richtech Robotics Class Action: Richtech Robotics Inc. is facing allegations of failing to disclose its non-existent collaboration with Microsoft during the class period from January 27 to January 29, 2026, misleading investors about the company's prospects, with a lead plaintiff motion deadline of April 3, 2026.
- Picard Medical Fraud Allegations: Picard Medical, Inc. is accused of being involved in a fraudulent stock promotion scheme and insider trading from September 2 to October 31, 2025, which misled investors about the company's operations, with a lead plaintiff motion deadline of April 3, 2026, potentially leading to significant financial losses.
- Plug Power Misrepresentation: Plug Power, Inc. is alleged to have materially overstated the availability of funds from a DOE loan during the class period from January 17 to November 13, 2025, resulting in distorted investor expectations regarding future projects, with a lead plaintiff motion deadline of April 3, 2026.
- Legal Consultation Reminder: The Law Offices of Frank R. Cruz remind affected investors to contact them to understand their legal rights, emphasizing that investors do not need to take immediate action to participate in these class actions and can choose to retain counsel or remain absent members.
See More
Multiple Companies Facing Class Action Lawsuits
- Richtech Robotics Lawsuit: Richtech Robotics Inc. (NASDAQ:RR) is facing allegations of false statements regarding a claimed partnership with Microsoft during the class period from January 27 to January 29, 2026, with a lead plaintiff deadline of April 3, 2026, urging investors to file motions.
- Plug Power Lawsuit: Plug Power, Inc. (NASDAQ:PLUG) is accused of overstating the availability of funds related to a DOE loan during the class period from January 17 to November 13, 2025, with a lead plaintiff deadline of April 3, 2026, encouraging shareholders with losses over $50,000 to reach out for legal counsel.
- Picard Medical Lawsuit: Picard Medical, Inc. (NYSE American:PMI) faces allegations of being involved in a fraudulent stock promotion scheme from September 2 to October 31, 2025, with a lead plaintiff deadline of April 3, 2026, prompting investors to file motions.
- BlackRock TCP Capital Lawsuit: BlackRock TCP Capital Corp. (NASDAQ:TCPC) is accused of failing to appropriately value investments from November 6, 2024, to January 23, 2026, with a lead plaintiff deadline of April 6, 2026, leading to an overstated net asset value and misleading statements about the company's operations.
See More
Class Action Lawsuit Filed Against Picard Medical, Inc.
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against Picard Medical in the Northern District of California on behalf of investors who purchased securities between September 2 and October 31, 2025, indicating significant legal risks for the company.
- Stock Price Crash: On October 24, 2025, Picard's stock price plummeted by 70%, from $13.30 to $3.99 per share, and has since continued to decline to approximately $2.00, reflecting extreme market concerns regarding the company's financial health.
- Fraud Allegations: The lawsuit alleges that Picard failed to disclose involvement in a fraudulent stock promotion scheme and insider trading activities, leading to substantial investor losses and highlighting severe deficiencies in corporate governance and transparency.
- Investor Rights Protection: Investors must apply by April 3, 2026, to be appointed as lead plaintiffs, demonstrating the law firm's commitment to protecting investor rights, which may influence future litigation strategies and the company's reputation.
See More
Picard Medical Securities Class Action Notice
- Class Action Initiation: Rosen Law Firm reminds investors who purchased Picard Medical (NYSE: PMI) securities between September 2 and October 31, 2025, to apply as lead plaintiffs by April 13, 2026, to participate in the class action without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that Picard Medical's management failed to disclose significant adverse facts regarding the company's business and operations during the securities trading period, misleading investors and impacting their decision-making.
- Fraudulent Activities Exposed: Specific allegations include involvement in a fraudulent stock promotion scheme through social media misinformation and insiders using offshore accounts to manipulate stock prices, severely harming investor interests.
- Law Firm's Expertise: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its professional capabilities and resource advantages in handling such cases.
See More
Reminder of Class Action Lawsuit for Picard Medical Investors
- Stock Price Crash: On October 23, 2025, Picard Medical's stock plummeted approximately 70% during after-hours trading, dropping from $13.20 to $3.99 per share, resulting in significant losses for investors and raising serious concerns about the company's financial health.
- False Promotion Exposed: Investigations revealed that Picard's stock was the target of an illicit social media promotion scheme, where impersonators of real financial advisors falsely touted the stock in online forums and social media, artificially inflating its price and harming investors' interests.
- Lawsuit Allegations: The class action lawsuit alleges that throughout the Class Period, the company failed to disclose material adverse facts regarding its business, operations, and prospects, specifically that it was affected by a fraudulent stock promotion scheme, misleading investors about its true condition.
- Investor Action Deadline: Investors must file a motion by April 3, 2026, to request appointment as lead plaintiff in this class action lawsuit to recover losses incurred due to false information, underscoring the importance of timely legal action.
See More
Picard Medical Securities Class Action Notice Issued
- Class Action Initiation: Rosen Law Firm has issued a reminder for investors who purchased Picard Medical (NYSE: PMI) securities between September 2 and October 31, 2025, to apply as lead plaintiffs by April 13, 2026, to protect their rights in the class action lawsuit.
- Transparent Fee Structure: Investors joining the class action will incur no upfront costs, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages more affected investors to participate.
- False Statements Exposed: The lawsuit alleges that Picard Medical failed to disclose significant adverse facts related to its business and securities trading during the class period, including fraudulent stock promotion schemes and insider trading, misleading investors about the company's true financial health.
- Law Firm's Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource capabilities in handling such cases.
See More
Multiple Companies Face Class Action Lawsuits
- Richtech Robotics Class Action: Richtech Robotics Inc. is facing allegations of failing to disclose its non-existent collaboration with Microsoft during the class period from January 27 to January 29, 2026, misleading investors about the company's prospects, with a lead plaintiff motion deadline of April 3, 2026.
- Picard Medical Fraud Allegations: Picard Medical, Inc. is accused of being involved in a fraudulent stock promotion scheme and insider trading from September 2 to October 31, 2025, which misled investors about the company's operations, with a lead plaintiff motion deadline of April 3, 2026, potentially leading to significant financial losses.
- Plug Power Misrepresentation: Plug Power, Inc. is alleged to have materially overstated the availability of funds from a DOE loan during the class period from January 17 to November 13, 2025, resulting in distorted investor expectations regarding future projects, with a lead plaintiff motion deadline of April 3, 2026.
- Legal Consultation Reminder: The Law Offices of Frank R. Cruz remind affected investors to contact them to understand their legal rights, emphasizing that investors do not need to take immediate action to participate in these class actions and can choose to retain counsel or remain absent members.
See More
Multiple Companies Facing Class Action Lawsuits
- Richtech Robotics Lawsuit: Richtech Robotics Inc. (NASDAQ:RR) is facing allegations of false statements regarding a claimed partnership with Microsoft during the class period from January 27 to January 29, 2026, with a lead plaintiff deadline of April 3, 2026, urging investors to file motions.
- Plug Power Lawsuit: Plug Power, Inc. (NASDAQ:PLUG) is accused of overstating the availability of funds related to a DOE loan during the class period from January 17 to November 13, 2025, with a lead plaintiff deadline of April 3, 2026, encouraging shareholders with losses over $50,000 to reach out for legal counsel.
- Picard Medical Lawsuit: Picard Medical, Inc. (NYSE American:PMI) faces allegations of being involved in a fraudulent stock promotion scheme from September 2 to October 31, 2025, with a lead plaintiff deadline of April 3, 2026, prompting investors to file motions.
- BlackRock TCP Capital Lawsuit: BlackRock TCP Capital Corp. (NASDAQ:TCPC) is accused of failing to appropriately value investments from November 6, 2024, to January 23, 2026, with a lead plaintiff deadline of April 6, 2026, leading to an overstated net asset value and misleading statements about the company's operations.
See More
Class Action Lawsuit Filed Against Picard Medical, Inc.
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against Picard Medical in the Northern District of California on behalf of investors who purchased securities between September 2 and October 31, 2025, indicating significant legal risks for the company.
- Stock Price Crash: On October 24, 2025, Picard's stock price plummeted by 70%, from $13.30 to $3.99 per share, and has since continued to decline to approximately $2.00, reflecting extreme market concerns regarding the company's financial health.
- Fraud Allegations: The lawsuit alleges that Picard failed to disclose involvement in a fraudulent stock promotion scheme and insider trading activities, leading to substantial investor losses and highlighting severe deficiencies in corporate governance and transparency.
- Investor Rights Protection: Investors must apply by April 3, 2026, to be appointed as lead plaintiffs, demonstrating the law firm's commitment to protecting investor rights, which may influence future litigation strategies and the company's reputation.
See More
Picard Medical Securities Class Action Notice
- Class Action Initiation: Rosen Law Firm reminds investors who purchased Picard Medical (NYSE: PMI) securities between September 2 and October 31, 2025, to apply as lead plaintiffs by April 13, 2026, to participate in the class action without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that Picard Medical's management failed to disclose significant adverse facts regarding the company's business and operations during the securities trading period, misleading investors and impacting their decision-making.
- Fraudulent Activities Exposed: Specific allegations include involvement in a fraudulent stock promotion scheme through social media misinformation and insiders using offshore accounts to manipulate stock prices, severely harming investor interests.
- Law Firm's Expertise: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its professional capabilities and resource advantages in handling such cases.
See More
Reminder of Class Action Lawsuit for Picard Medical Investors
- Stock Price Crash: On October 23, 2025, Picard Medical's stock plummeted approximately 70% during after-hours trading, dropping from $13.20 to $3.99 per share, resulting in significant losses for investors and raising serious concerns about the company's financial health.
- False Promotion Exposed: Investigations revealed that Picard's stock was the target of an illicit social media promotion scheme, where impersonators of real financial advisors falsely touted the stock in online forums and social media, artificially inflating its price and harming investors' interests.
- Lawsuit Allegations: The class action lawsuit alleges that throughout the Class Period, the company failed to disclose material adverse facts regarding its business, operations, and prospects, specifically that it was affected by a fraudulent stock promotion scheme, misleading investors about its true condition.
- Investor Action Deadline: Investors must file a motion by April 3, 2026, to request appointment as lead plaintiff in this class action lawsuit to recover losses incurred due to false information, underscoring the importance of timely legal action.
See More
